How much funding has Avalo Therapeutics raised?

Avalo Therapeutics has raised $185.0M in total funding, most recently a Corporate Round.

Who are Avalo Therapeutics's investors?

Avalo Therapeutics's investors include OrbiMed.

When was Avalo Therapeutics founded?

Avalo Therapeutics was founded in 2021.

Where is Avalo Therapeutics headquartered?

Avalo Therapeutics is headquartered in Baltimore, Maryland, United States.

What industry is Avalo Therapeutics in?

Avalo Therapeutics operates in Biotech, Healthcare.

How many employees does Avalo Therapeutics have?

Avalo Therapeutics has 11-50 employees.

Avalo Therapeutics

IPO

Homepage - AvaloTx

Public · Baltimore, United States · Founded 2021 · $185.0M raised

Biotech

Healthcare

Headquarters: Baltimore, Maryland
Employees: 11–50
Founded: 2021
Business Model: B2B
Website: avalotx.com

Total Funding: $185.0M
Last Round: $185.0M Corporate RoundMar 2024
Rounds: 1
Type: Public

About

Avalo Therapeutics is a clinical-stage biopharmaceutical company focused exclusively on developing treatments for immune-mediated inflammatory diseases. The company targets the IL-1β pathway, which drives inflammatory processes across numerous conditions. Its lead asset, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody with positive Phase 2 data for hidradenitis suppurativa and potential applications across multiple other immune-mediated diseases.

Summary

Avalo Therapeutics is a Biotech company based in Baltimore, United States, founded in 2021. It has raised $185.0M in total across 1 round, most recently a $185.0M Corporate Round round in Mar 2024. Investors include OrbiMed.

LinkedIn X (Twitter)